(Q37084296)

18 August 2017

1 reference

title

Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention (English)

1 reference

18 August 2017

0 references

Armin Steinmetz

1

1 reference

18 August 2017

language of work or name

1 reference

1 May 2008

1 reference

Diabetes - Metabolism: Research and Reviews

18 August 2017

published in

1 reference

18 August 2017

volume

24

1 reference

18 August 2017

issue

4

1 reference

18 August 2017

page(s)

286-293

1 reference

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

18 August 2017

cites work

1 reference

Diabetes: a time for excitement-and concern. Hopeful signs exist that the ravages of diabetes can be tamed

21 January 2018

1 reference

Lipids, diabetes, and coronary heart disease: insights from the Framingham Study.

21 January 2018

1 reference

7 January 2021

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

1 reference

7 January 2021

Microvascular complications. Retinopathy and nephropathy

1 reference

7 January 2021

Diabetic nephropathy and retinopathy

1 reference

7 January 2021

Diabetic neuropathies

1 reference

7 January 2021

Prevalence of cardiovascular and renal complications in older adults with normal or impaired glucose tolerance or NIDDM. A population-based study

1 reference

7 January 2021

ABC of arterial and venous disease: vascular complications of diabetes

1 reference

7 January 2021

Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes: early treatment diabetic retinopathy study report no. 27

1 reference

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

7 January 2021

Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study

1 reference

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

7 January 2021

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

7 January 2021

Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials

1 reference

7 January 2021

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

1 reference

7 January 2021

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

7 January 2021

Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)

1 reference

7 January 2021

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

1 reference

7 January 2021

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

7 January 2021

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

1 reference

7 January 2021

Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study

1 reference

7 January 2021

Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives

1 reference

7 January 2021

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials

1 reference

7 January 2021

Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate

1 reference

7 January 2021

Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).

1 reference

7 January 2021

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

1 reference

7 January 2021

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

7 January 2021

Correction to the FIELD study report.

1 reference

7 January 2021

Leptin-regulated endocannabinoids are involved in maintaining food intake

1 reference

7 January 2021

The anti-obesity effect of rimonabant is associated with an improved serum lipid profile

1 reference

7 January 2021

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

1 reference

7 January 2021

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

7 January 2021

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

1 reference

7 January 2021

The role of lipids in the development of diabetic microvascular complications: implications for therapy

1 reference

7 January 2021

The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering?

1 reference

7 January 2021

Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia

1 reference

7 January 2021

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).

1 reference

7 January 2021

Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions

1 reference

7 January 2021

Fibrates in combination with statins in the management of dyslipidemia

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.806

1 reference

18 August 2017

1 reference